Ernexa Therapeutics: Clear Street ends 13G reporting

Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation.

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation. The amendment states Clear Street's beneficial ownership is 0 shares, representing 0.0% of the common stock and therefore below the 5% reporting threshold.

The amendment explains no reporting obligation existed at the time of the original filing and is signed by John DiBacco, Head of Markets Trading on 05/20/2026.

Insights

Securities Compliance Counsel

Routine termination of a Schedule 13G reporting obligation due to zero beneficial ownership.

The amendment formally records that Clear Street LLC holds 0 shares (0.0%) of the issuer's common stock, so it no longer meets the 5% reporting threshold under the ownership reporting regime. The filing states this is the basis for terminating the prior filing obligation.

Filing is administrative in nature; subsequent investor disclosures will reflect any new ownership that meets reporting thresholds. Timing and cash‑flow treatment are not applicable in the provided excerpt.

Key Figures

Beneficial ownership: 0 shares Percent of class: 0.0% CUSIP: 114082407 +2 more

5 metrics

Beneficial ownership 0 shares Amount beneficially owned stated in Item 4

Percent of class 0.0% Percent of class stated in Item 4

CUSIP 114082407 Issuer common stock CUSIP on cover

Reporting threshold 5% threshold Reference to the 5% reporting threshold under Schedule 13G

Signature date 05/20/2026 Signed by Head of Markets Trading

Key Terms

Schedule 13G/A, Beneficially owned, 5% reporting threshold

3 terms

Schedule 13G/A regulatory

"Amendment to a Schedule 13G filed by Clear Street LLC terminates reporting obligation"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned regulatory

"Item 4 states Amount beneficially owned: 0"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

5% reporting threshold regulatory

"This amendment is filed as the beneficial ownership does not meet or exceed the 5% reporting threshold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ernexa Therapeutics (ERNA) Schedule 13G/A amendment mean?

It terminates Clear Street LLC's reporting obligation because their ownership is reported as 0 shares (0.0%). The amendment states Clear Street did not meet the 5% reporting threshold, so the prior filing is ended and no further joint filings from that group are required.

Who filed the amendment for ERNA and when was it signed?

The amendment was filed by Clear Street LLC and signed by John DiBacco as Head of Markets Trading on 05/20/2026. The cover shows the issuer as Ernexa Therapeutics Inc. with CUSIP 114082407.

How much of ERNA does Clear Street LLC beneficially own after the amendment?

Clear Street LLC is reported to beneficially own 0 shares, equal to 0.0% of the common stock. The filing explicitly states this zero ownership as the reason it does not meet the 5% reporting threshold.

Does this amendment indicate any transaction or cash flow for ERNA?

No transaction or cash flow is disclosed in the amendment; it only reports ownership status as 0 shares. The filing explains the reporting obligation is terminated because ownership falls below the statutory threshold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:50 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Ernexa Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

114082407

(CUSIP Number)

05/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 114082407

1

Names of Reporting Persons

Clear Street LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

BD

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ernexa Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 1035 Cambridge Street Suite 18A Cambridge MA 02141
Item 2.
(a)	Name of person filing: Clear Street LLC
(b)	Address or principal business office or, if none, residence: 4 WORLD TRADE CENTER, 150 Greenwich St Floor 45 New York, NY 10007
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 114082407
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. This amendment is being filed as the beneficial ownership of Clear Street LLC does not meet or exceed the 5% reporting threshold required under 13G. As such, no reporting obligation existed at the time of the original filing, and this amendment is filed to terminate that reporting obligation.

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Clear Street LLC

Signature:	John DiBacco
Name/Title:	Head of Markets Trading
Date:	05/20/2026